Imperial inventors have identified an EP2 receptor agonist with an application as a novel tocolytic for the management of pre-term labour. It is long-acting, inhibits contractility and does not activate pro-inflammatory pathways.
SLIC-CAGE is a novel development of the cap-trapper CAGE protocol which can generate complex high-quality libraries for as little as 5-10 nanograms of cellular RNA.
18F-FET-βAG-TOCA is a novel, ‘click’ 18F-labelled octreotate PET imaging radiopharmaceutical that detects tumour lesions in patients with neuroendocrine tumours (NETs).
A late-stage, pre-clinically validated inhibitor of MAP4K4 for a range of indications including anthracycline cardiotoxicity
A simple, whole blood 2-gene expression signature that distinguishes bacterial infection from both viral infection and childhood inflammatory diseases.
DTP3 is a first-in-class GADD45β/MKK7 inhibitor targeting the NF-κB pathway
A novel tracer, 18F-ICMT-11, targeting specific biological processes to improve detection of tumours that are often missed by FDG PET imaging
A novel, high capacity humidifying device which can rapidly humidify large spaces in seconds with multiple applications, including humidification and air purification.
A tool for predicting Alzheimer’s Disease (AD) with greater accuracy than conventional methods.
The invention herein refers to a suite of broad neutralising monoclonal antibodies (bnMABs) isolated to be used for treatment of coronaviruses with a focus on SARS-CoV-2 (2019-nCoV). Four potential human monoclonal antibodies have been identified with broad neutralising activitiesin coronavirus(SARS and MERS).